Bio Plus Co

Bio Plus Co Interest Expense

The Interest Expense of Bio Plus Co (099430.KQ) as of Oct 22, 2026 is -4.16 B KRW. In the previous year, Interest Expense was 3.76 B KRW — a change of -210.55% (lower).

Interest Expense

-4.16 BKRW

YoY

-210.55%

Last updated:

Interest Expense of Bio Plus Co is 2024 -4.16 B KRW. Interest Expense of Bio Plus Co was 2023 3.76 B KRW. It decreases by -210.55% lower compared to the previous year.

The Bio Plus Co Interest Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Expense
Date
Interest Expense
Jan 1, 2018
-1.10 B KRW
Jan 1, 2019
-71.51 M KRW
Jan 1, 2020
-186.17 M KRW
Jan 1, 2021
-2.36 B KRW
Jan 1, 2022
3.04 B KRW
Jan 1, 2023
3.76 B KRW
Jan 1, 2024
-4.16 B KRW
The Bio Plus Co Interest Expense history
YEARInterest ExpenseYoY
-4.16 BKRW-210.55%
3.76 BKRW+23.70%
3.04 BKRW-228.85%
-2.36 BKRW+1,168.47%
-186.17 MKRW+160.35%
-71.51 MKRW-93.50%
-1.10 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Plus Co Stock analysis

What does Bio Plus Co do? BioPlus Co., Ltd. generates revenue through the manufacturing and sale of dermal fillers, primarily hyaluronic acid fillers for temporary facial wrinkle improvement. The company also produces and sells anti-adhesion agents to prevent surgical adhesions, biomaterials for joint tissue repair, and other tissue restoration products. These products are supplied to medical professionals and healthcare facilities requiring cosmetic and surgical solutions. The firm targets the medical and cosmetic sectors, focusing on tissue restoration applications for both aesthetic and functional needs. The company's product portfolio includes biomaterials for tissue restoration, specifically designed for temporary facial wrinkle correction, anti-adhesion solutions for surgical sites, and joint tissue repair materials. These offerings cater to healthcare providers seeking advanced biomaterials for patient care. BioPlus Co., Ltd. serves the medical industry by providing specialized products that address both cosmetic enhancement and post-surgical recovery requirements. BioPlus Co., Ltd. operates within the biomaterials sector, focusing on dermal fillers and tissue repair solutions. Its products are utilized by medical practitioners for facial aesthetics and surgical applications. The company's revenue streams are derived from direct sales of these biomaterial products to healthcare institutions and professionals in the medical field. Bio Plus Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Plus Co stock

Interest Expense of Bio Plus Co is -4.16 B KRW in 2024.

Interest Expense of Bio Plus Co changed from 3.76 B KRW to -4.16 B KRW, representing a -210.55% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Expense Bio Plus Co since 2006 – with annual values, charts, and detailed analysis.

Interest expense represents the cost of borrowing. Higher interest expenses can indicate a highly leveraged company.

Interest Expense's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Interest Expense's Bio Plus Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Bio Plus Co

All Key Metrics — Bio Plus Co